The plant family Amaryllidaceae is recognizable for its esthetic floral characteristics, its widespread usage in traditional medicine as well as its unique alkaloid principles. Few alkaloid-producing families rival the Amaryllidaceae in terms of the diversity of its structures as well as their wide applicability on the biological landscape. In particular, cytotoxic effects have come to be a dominant theme in the biological properties of Amaryllidaceae alkaloids. To this extent, a significant number of structures have been subjected to in vitro studies in numerous cell lines from which several targets have been identified as promising chemotherapeutics. By contrast, in vivo models of study involving these alkaloids have been carried out to a lesser extent and should prove crucial in the continued development of a clinical target such as pancratistatin. This survey examines the cytotoxic effects of Amaryllidaceae alkaloids in vivo and contrasts these against the corresponding in vitro effects.
GrahamJG, QuinnML, FabricantDS, FarnsworthNR. (2000) Plants used against cancer – an extension of the work of Jonathan Hartwell. Journal of Ethnopharmacology, 73, 347–377.
2.
Caamal-FuentesE, Torres-TapiaLW, Simá-PolancoP, Peraza-SánchezSR, Moo-PucR. (2011) Screening of plants used in Mayan traditional medicine to treat cancer-like symptoms. Journal of Ethnopharmacology, 135, 719–724.
3.
NairJJ, Van StadenJ. (2013) Pharmacological and toxicological insights to the South African Amaryllidaceae. Food and Chemical Toxicology, 62, 262–275.
4.
KornienkoA, EvidenteA. (2008) Chemistry, biology and medicinal potential of narciclasine and its congeners. Chemical Reviews, 108, 1982–2014;
5.
IngrassiaL, LefrancF, MathieuV, DarroF, KissR. (2008) Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents. Transonal Oncology, 1, 1–13.
6.
NairJJ, BastidaJ, ViladomatF, Van StadenJ. (2012) Cytotoxic agents of the crinane series of Amaryllidaceae alkaloids. Natural Product Communications, 7, 1677–1688.
7.
NairJJ, Van StadenJ. (2014) Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. Natural Product Communications, 9, 1193–1210;
8.
Lamoral-TheysD, DecaesteckerC, MathieuV, DuboisJ, KornienkoA, KissR, EvidenteA, PottierL. (2010) Lycorine and its derivatives for anticancer drug design. Mini-Review in Medicinal Chemistry, 10, 41–50.
9.
NairJJ, RárováL, StrnadM, BastidaJ, Van StadenJ. (2015) Mechanistic insights to the cytotoxicity of Amaryllidaceae alkaloids. Natural Product Communications, 10, 171–182.
10.
BastidaJ, LavillaR, ViladomatF. (2006) Chemical and biological aspects of Narcissus alkaloids. In The Alkaloids.CordellGA (Ed). Elsevier, Amsterdam, Netherlands, 87–179.
11.
ViladomatF, BastidaJ, CodinaC, NairJJ, CampbellWE. (1997) Alkaloids of the South African Amaryllidaceae. In Recent Research Developments in Phytochemistry. Vol. 1, PandalaiSG (Ed). Research Signpost Publishers, Trivandrum, India, 131–171.
12.
NairJJ, BastidaJ, CodinaC, ViladomatF, Van StadenJ. (2013) Alkaloids of the South African Amaryllidaceae: a review. Natural Product Communications, 8, 1335–1550.
CraggGM, NewmanDJ. (2005) Plants as a source of anti-cancer agents. Journal of Ethnopharmacology, 100, 72–79;
15.
NewmanDJ, CraggGM. (2007) Natural products as sources of new drugs over the last 25 years. Journal of Natural Products, 70, 461–477;
16.
PanL, ChaiH, KinghornAD. (2010) The continuing search for antitumor agents from higher plants. Phytochemistry Letters, 3, 1–8;
17.
NewmanDJ, CraggGM. (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of Natural Products, 75, 311–335.
18.
FitzgeraldDB, HartwellJL, LeiterJ. (1958) Tumor-damaging activity in plant families showing antimalarial activity. Amaryllidaceae. Journal of the National Cancer Institute, 20, 763–774.
19.
HartwellJL. (1967) Plants used against cancer. A survey. Lloydia, 30, 379–436.
20.
CharlsonAJ. (1980) Antineoplastic constituents of some southern African plants. Journal of Ethnopharmacology, 2, 323–335.
Thi Ngoc TramN, ZvetkovaE, NikolovaE, KatzarovaE, KostovG, YanchevI, BaichevaO. (1999) A novel in vitro and in vivo T-lymphocyte activating factor in Crinum latifolium (L.) aqueous extracts. Experimental Pathology and Parasitology, 3, 21–26;
25.
MiceliMC, ParnesJR. (1993) Role of CD4 and CD8 in T cell activation and differentiation. Advances in Immunology, 53, 59–122;
26.
ChanJKC, NgCS, HuiPK. (1988) A simple guide to the terminology and application of leucocyte monoclonal antibodies. Histopathology, 12, 461–480.
27.
Thi Ngoc TramN, YanchevI, ZvetkovaE, DinevaJ, KatzarovaE, KostovG, SvilenovD, IlievaI, ShalamanovP. (2001) Retarded growth of chemically-induced with 20-methylcholanthrene tumors in rats under the action of cold-hot aqueous extracts (decoctions) from Vietnamese plant Crinum latifolium (L.). Experimental Pathology and Parasitology, 4, 9–12.
28.
HoughtonPJ, RenY, HowesM-J. (2006) Acetylcholinesterase inhibitors from plants and fungi. Natural Product Reports, 23, 181–199.
29.
CeriottiG. (1967) Narciclasine: an antimitotic substance from Narcisssus bulbs. Nature, 213, 595–596;
FurusawaE, FurusawaS, MorimotoS, CuttingW. (1971) Therapeutic activity of Narcissus alkaloid on Rauscher leukemia and comparison with standard drugs. Proceedings of the Society for Experimental Biology and Medicine, 136, 1168–1173;
32.
FurusawaE, SuzukiN, RamanathanS, FurusawaS, CuttingW. (1972) Effect of long-term administration of Narcissus alkaloid on Rauscher leukemia and combinations with standard drugs. Proceedings of the Society for Experimental Biology and Medicine, 140, 1034–1040;
33.
SuzukiN, TaniS, FurusawaS, FurusawaE. (1974) Therapeutic activity of Narcissus alkaloid on Rauscher leukemia: antiviral effect in vitro and rational drug combination in vivo. Proceedings of the Society for Experimental Biology and Medicine, 145, 771–777.
34.
FurusawaE, IrieH, CombsD, WildmanWC. (1980) Therapeutic activity of pretazettine on Rauscher leukemia: comparison with the related Amaryllidaceae alkaloids. Experimental Chemotherapy, 26, 36–45.
35.
GhosalS, LochanR, KumarAshutosh Y, SrivastavaRS. (1985) Alkaloids of Haemanthus kalbreyeri. Phytochemistry, 24, 1825–1828;
36.
GhosalS, ShanthyA, KumarA, KumarY. (1985) Palmilycorine and lycoriside: acyloxy and acylglucosyloxy alkaloids from Crinum asiaticum. Phytochemistry, 24, 2703–2706;
37.
GhosalS, SinghSK. (1986) Chemical constituents of Amaryllidaceae. Part 24. Crinafoline and crinafolidine, two antitumor alkaloids from Crinum latifolium. Journal of Chemical Research (S), 312–313;
38.
GhosalS, SinghSK, KumarY, UnnikrishnanS, ChattopadhyayS. (1988) The role of ungeremine in the growth–inhibiting and cytotoxic effects of lycorine: evidence and speculation. Planta Medica, 54, 114–116.
39.
Zee-ChengRK-Y, YanS-J, ChengCC. (1978) Antileukemic activity of ungeremine and related compounds. Preparation of analogues of ungeremine by a practical photochemical reaction. Journal of Medicinal Chemistry, 21, 199–203;
40.
BarthelmesHU, NiederbergerE, RothT, SchulteK, TangWC, BoegeF, FiebigH-H, EisenbrandG, MarkoD. (2001) Lycobetaine as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells. British Journal of Cancer, 85, 1585–1591.
41.
MinBS, GaoJJ, NakamuraN, KimYH, HattoriM. (2001) Cytotoxic alkaloids and a flavan from the bulbs of Crinum asiaticum var. japonicum. Chemical and Pharmaceutical Bulletin, 49, 1217–1219;
42.
LiuJ, HuW, HeL, YeM, LiY. (2004) Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis. FEBS Letters, 578, 245–250;
43.
LiuJ, LiY, TangLJ, ZhangGP, HuWX. (2007) Treatment of lycorine on SCID mice model with human APL cells. Biomedicine & Pharmacotherapy, 61, 229–234;
44.
Lamoral-TheysD, AndolfiA, Van GoietsenovenG, CimminoA, Le CalvéB, WauthozN, MégalizziV, GrasT, BruyèreC, DuboisJ, MathieuV, KornienkoA, KissR, EvidenteA. (2009) Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. Journal of Medicinal Chemistry, 52, 6244–6256;
CaoZ, YuD, FuS, ZhangG, PanY, BaoM, TuJ, ShangB, GuoP, YangP, ZhouQ. (2013) Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicology Letters, 218, 174–185;
47.
ManiotisAJ, FolbergR, HessA, SeftorEA, GardnerLM, Pe'erJ, TrentJM, MeltzerPS, HendrixMJ. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. American Journal of Pathology, 155, 739–752.
48.
AlarcónM, CeaG, WeigertG. (1986) Clastogenic effect of hippeastidine (HIPP) (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine). Bulletin of Environmental Contamination and Toxicology, 37, 508–512;
49.
GriffinC, ShardaN, SoodD, NairJJ, McNultyJ, PandeyS. (2007) Selective cytotoxicity of pancratistatin-related natural Amaryllidaceae alkaloids: evaluation of the activity of two new compounds. Cancer Cell International, 7, 10–16;
50.
GuoG, YaoG, ZhanG, HuY, YueM, ChengL, LiuY, YeQ, QingG, ZhangY, LiuH. (2014) N-methylhemeanthidine chloride, a novel Amaryllidaceae alkaloid, inhibits pancreatic cancer cell proliferation via down-regulating AKT activation. Toxicology and Applied Pharmacology, 280, 475–483;
51.
MoldovanG-L, PfanderB, JentschS. (2007) PCNA, the maestro of the replication fork. Cell, 129, 665–679;
52.
CohenGM. (1997) Caspases: the executioners of apoptosis. Biochemical Journal, 326, 1–16.
53.
BeijnenJH, FloraKP, HalbertGW, HenrarREC, SlackJA. (1995) CRC/EORTC/NCI joint formulation working party: experiences in the formulation of investigational cytotoxic drugs. British Journal of Cancer, 72, 210–218;
MikamiM, KitaharaM, KitanoM, ArikiY, MimakiY, SashidaY, YamazakiM, YuiS. (1999) Suppressive activity of lycoricidinol (narciclasine) against cytotoxicity of neutrophil-derived calprotectin and its suppressive effect on rat adjuvant arthritis model. Biological and Pharmaceutical Bulletin, 22, 674–678;
56.
YuiS, NakataniY, MikamiM. (2003) Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biological and Pharmaceutical Bulletin, 26, 753–760;
57.
IngrassiaL, LefrancF, DewelleJ, PottierL, MathieuV, Spiegl-KreineckerS, SauvageS, El YazidiM, DehouxM, BergerW, Van QuaquebekeE, KissR. (2009) Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. Journal of Medicinal Chemistry, 52, 1100–1114;
58.
LefrancF, SauvageS, Van GoietsenovenG, MégalizziV, Lamoral-TheysD, DebeirO, Spiegl-KreineckerS, BergerW, MathieuV, DecaesteckerC, KissR. (2009) Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Molecular Cancer Therapeutics, 8, 1739–1750;
59.
DumontP, IngrassiaL, RouzeauS, RibaucourF, ThomasS, RolandI, DarroF, LefrancF, KissR. (2007) The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia, 9, 766–776;
60.
Van GoietsenovenG, HuttonJ, BeckerJ-P, LallemandB, RobertF, LefrancF, PirkerC, VandenbusscheG, Van AntwerpenP, EvidenteA, BergerW, PrévostM, PelletierJ, KissR, KinzyTG, KornienkoA, MathieuV. (2010) Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB Journal, 24, 4575–4584;
61.
Van GoietsenovenG, MathieuV, LefrancF, KornienkoA, EvidenteA, KissR. (2013) Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers. Medicinal Research Reviews, 33, 439–455.
62.
PettitGR, MelodyN, HeraldDL. (2004) Antineoplastic Agents. 511. Direct phosphorylation of phenpanstatin and pancratistatin. Journal of Natural Products, 67, 322–327;
63.
ShnyderSD, CooperPA, MillingtonNJ, GillJH, BibbyMC. (2008) Sodium pancratistatin 3,4-O-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in human colon tumor model. Journal of Natural Products, 71, 321–324;
64.
DarkGG, HillSA, PriseVE, TozerGM, PettitGR, ChaplinDJ. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Research, 57, 1829–1834;
65.
MutsugaM, KojimaK, YamashitaM, OhnoT, OgiharaY, InoueM. (2002) Inhibition of cell cycle progression through specific phase by pancratistatin derivatives. Biological and Pharmaceutical Bulletin, 25, 223–228;
66.
McLachlanA, KekreN, McNultyJ, PandeyS. (2005) Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce mitosis. Apoptosis, 10, 619–630;
67.
KekreN, GriffinC, McNultyJ, PandeyS. (2005) Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer Chemotherapy and Pharmacology, 56, 29–38;
68.
PandeyS, KekreN, NaderiJ, McNultyJ. (2005) Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin. Artificial Cells, Blood Substitutes, and Biotechnology, 33, 1–17;
69.
SiedlakowskiP, McLachlan-BurgessA, GriffinC, TirumalaiSS, McNultyJ, PandeyS. (2008) Synergy of pancratistatin and tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biology & Therapy, 7, 376–384;
70.
GriffinC, HammC, McNultyJ, PandeyS. (2010) Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells. Cancer Cell International, 10, 1–7;
71.
GriffinC, McNultyJ, PandeyS. (2011) Pancratistatin induces apoptosis and autophagy in metastatic prostate cancer cells. International Journal of Oncology, 38, 1549–1556;
72.
GriffinC, KarnikA, McNultyJ, PandeyS. (2011) Pancratistatin selectively targets cancer cell mitochondria and reduces growth of human colon tumor xenografts. Molecular Cancer Therapeutics, 10, 57–68.
